APA (7th ed.) Citation

J, N., M, K., A, I., T, B., M, S., M, H., . . . D, D. (2026). The In Vivo Effect of Amorphous Drug Nanoprecipitates on the Intestinal Absorption of the PROTACs ARV-110 (Bavdeglutamide) and ARV-471 (Vepdegestrant). Molecular pharmaceutics, 23(6), 3445. https://doi.org/10.1021/acs.molpharmaceut.6c00207

Chicago Style (17th ed.) Citation

J, Niessen, Koziolek M, Indulkar A, Borchardt T, Sjöblom M, Hedeland M, Lennernäs H, and Dahlgren D. "The In Vivo Effect of Amorphous Drug Nanoprecipitates on the Intestinal Absorption of the PROTACs ARV-110 (Bavdeglutamide) and ARV-471 (Vepdegestrant)." Molecular Pharmaceutics 23, no. 6 (2026): 3445. https://doi.org/10.1021/acs.molpharmaceut.6c00207.

MLA (9th ed.) Citation

J, Niessen, et al. "The In Vivo Effect of Amorphous Drug Nanoprecipitates on the Intestinal Absorption of the PROTACs ARV-110 (Bavdeglutamide) and ARV-471 (Vepdegestrant)." Molecular Pharmaceutics, vol. 23, no. 6, 2026, p. 3445, https://doi.org/10.1021/acs.molpharmaceut.6c00207.